Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Colorectal cancer is a leading cause of cancer-related death in the world and there is an urgent need for new strategies to combat this disease. Findings from several independent laboratories have converged on cGMP signaling as an exciting new therapeutic target, but the mechanisms remain controversial. A key intracellular effector of cGMP is protein kinase G (PKG). This article reviews the scientific literature concerning PKG effects on tumor development and progression, and discusses possible strategies for its exploitation in future cancer therapies. Studies from several independent laboratories have described novel anti-tumor effects of PKG in colon cancer cells that include inhibition of tumor growth and angiogenesis. While more preclinical research is warranted to better understand signaling mechanisms, these properties support the notion that PKG is a novel cancer target.

Original languageEnglish (US)
Pages (from-to)367-376
Number of pages10
JournalExpert Opinion on Therapeutic Targets
Issue number3
StatePublished - Mar 2008


  • Angiogenesis
  • Apoptosis
  • Colon cancer
  • Metastasis
  • Nitric oxide
  • PKG
  • Phosphodiesterase
  • Uroguanylin
  • cGMP

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this